[Lymphatic filariasis transmission assessment survey in schools three years after stopping mass drug treatment with albendazole and ivermectin in the 7 endemic districts in Togo].
Identifieur interne : 000059 ( France/Analysis ); précédent : 000058; suivant : 000060[Lymphatic filariasis transmission assessment survey in schools three years after stopping mass drug treatment with albendazole and ivermectin in the 7 endemic districts in Togo].
Auteurs : A M Dorkenoo [France] ; Y K Sodahlon ; R N Bronzan ; K. Yakpa ; E. Sossou ; A. Ouro-Medeli ; M. Teko ; A. Seim ; E. MathieuSource :
- Bulletin de la Societe de pathologie exotique (1990) [ 0037-9085 ] ; 2015.
Descripteurs français
- KwdFr :
- Albendazole (administration et posologie), Albendazole (usage thérapeutique), Animaux, Antigènes d'helminthe (sang), Antihelminthiques (administration et posologie), Antihelminthiques (usage thérapeutique), Dépistage systématique, Enfant, Enquêtes de santé, Femelle, Filariose lymphatique (), Filariose lymphatique (diagnostic), Filariose lymphatique (transmission), Filariose lymphatique (épidémiologie), Guides de bonnes pratiques cliniques comme sujet, Humains, Immunochromatographie (instrumentation), Ivermectine (administration et posologie), Ivermectine (usage thérapeutique), Maladies endémiques (), Microfilaria (isolement et purification), Mâle, Organisation mondiale de la santé, Parasitémie (diagnostic), Parasitémie (parasitologie), Programmes gouvernementaux, Promotion de la santé (organisation et administration), Services de santé scolaire, Togo (épidémiologie), Wuchereria bancrofti (immunologie), Wuchereria bancrofti (isolement et purification), Établissements scolaires, Études par échantillonnage, Études transversales, Évaluation de programme.
- MESH :
- administration et posologie : Albendazole, Antihelminthiques, Ivermectine.
- diagnostic : Filariose lymphatique, Parasitémie.
- immunologie : Wuchereria bancrofti.
- isolement et purification : Microfilaria, Wuchereria bancrofti.
- organisation et administration : Promotion de la santé.
- parasitologie : Parasitémie.
- sang : Antigènes d'helminthe, Immunochromatographie.
- usage thérapeutique : Albendazole, Antihelminthiques, Filariose lymphatique, Ivermectine.
- épidémiologie : Filariose lymphatique, Togo.
- Animaux, Dépistage systématique, Enfant, Enquêtes de santé, Femelle, Filariose lymphatique, Guides de bonnes pratiques cliniques comme sujet, Humains, Maladies endémiques, Mâle, Organisation mondiale de la santé, Programmes gouvernementaux, Services de santé scolaire, Établissements scolaires, Études par échantillonnage, Études transversales, Évaluation de programme.
English descriptors
- KwdEn :
- Albendazole (administration & dosage), Albendazole (therapeutic use), Animals, Anthelmintics (administration & dosage), Anthelmintics (therapeutic use), Antigens, Helminth (blood), Child, Cross-Sectional Studies, Elephantiasis, Filarial (diagnosis), Elephantiasis, Filarial (epidemiology), Elephantiasis, Filarial (prevention & control), Elephantiasis, Filarial (transmission), Endemic Diseases (prevention & control), Female, Government Programs, Health Promotion (organization & administration), Health Surveys, Humans, Immunochromatography (instrumentation), Ivermectin (administration & dosage), Ivermectin (therapeutic use), Male, Mass Screening, Microfilariae (isolation & purification), Parasitemia (diagnosis), Parasitemia (parasitology), Practice Guidelines as Topic, Program Evaluation, Sampling Studies, School Health Services, Schools, Togo (epidemiology), World Health Organization, Wuchereria bancrofti (immunology), Wuchereria bancrofti (isolation & purification).
- MESH :
- chemical , administration & dosage : Albendazole, Anthelmintics, Ivermectin.
- chemical , blood : Antigens, Helminth.
- chemical , therapeutic use : Albendazole, Anthelmintics, Ivermectin.
- diagnosis : Elephantiasis, Filarial, Parasitemia.
- epidemiology : Elephantiasis, Filarial, Togo.
- immunology : Wuchereria bancrofti.
- instrumentation : Immunochromatography.
- isolation & purification : Microfilariae, Wuchereria bancrofti.
- organization & administration : Health Promotion.
- parasitology : Parasitemia.
- prevention & control : Elephantiasis, Filarial, Endemic Diseases.
- transmission : Elephantiasis, Filarial.
- Animals, Child, Cross-Sectional Studies, Female, Government Programs, Health Surveys, Humans, Male, Mass Screening, Practice Guidelines as Topic, Program Evaluation, Sampling Studies, School Health Services, Schools, World Health Organization.
Abstract
The aim of this study is to verify the level of transmission of lymphatic filariasis three years after stopping mass drug treatment in the 7 endemic districts in Togo. The survey was conducted in 2012 in Togo's 7 endemic districts grouped into four evaluation units (EU) using the WHO-recommended transmission assessment survey (TAS) protocol. Children aged 6-7 years were screened for Wuchereria bancofti antigen using the immunochromatographic card (ICT) method. A cluster sampling method was used to select eligible children in schools as the net primary-school enrolment ratio is greater than or equal to 75% in each of the four EUs. The number of children and schools to be selected in each EU, the randomization list for the selection of these children and the critical cut-off number of positive cases not to exceed were automatically generated using the Survey Sample Builder (SSB) tool, (NTD Support Center, Atlanta, Ga, USA). For confirmation, positive cases were subsequently tested for microfilaremia using nocturnal thick blood smear and for filarial antigen using Og4C3 antigen ELISA (TropBio ELISA Kit®, Townsville, Queensland, Australia). An EU is considered to have passed the test successfully (it is assumed that transmission can no longer be sustained), when the number of positive cases is below the critical cut-off number set by the SSB, which is roughly equivalent to 2% prevalence. Of the 1 706 children surveyed in Kpendjal-Tone's EU, 1 549 in Binah-Doufelgou's EU, 1 550 in Kozah's EU and the 1 575 in Amou-Haho's EU, 8 (0.46%), 1 (0.08%), 0 (0.00%) and 4 (0.25%) ICT positive cases respectively were detected. The number of positive ICT tests was well below 18, the critical cut number for each of the 4 EUs. All 13 ICT positive cases tested negative for nocturnal microfilaremia and Og4C3 ELISA. We conclude that all four EU passed the TAS with success, and the transmission of Wuchereria bancrofti is no longer likely to be sustained in the 7 endemic districts in Togo 3 years after stopping the MDA. A new TAS will be carried out in 2015, after which, if the results are still good, the country will submit a dossier to WHO for verification of the elimination of lymphatic filariasis.
DOI: 10.1007/s13149-014-0408-z
PubMed: 25476256
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001156
- to stream PubMed, to step Curation: 001156
- to stream PubMed, to step Checkpoint: 001156
- to stream Ncbi, to step Merge: 006E07
- to stream Ncbi, to step Curation: 006E07
- to stream Ncbi, to step Checkpoint: 006E07
- to stream Main, to step Merge: 001585
- to stream Main, to step Curation: 001583
- to stream Main, to step Exploration: 001583
- to stream France, to step Extraction: 000059
Links to Exploration step
pubmed:25476256Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Lymphatic filariasis transmission assessment survey in schools three years after stopping mass drug treatment with albendazole and ivermectin in the 7 endemic districts in Togo].</title><author><name sortKey="Dorkenoo, A M" sort="Dorkenoo, A M" uniqKey="Dorkenoo A" first="A M" last="Dorkenoo">A M Dorkenoo</name><affiliation wicri:level="1"><nlm:affiliation>Ministère de la Santé du Togo, BP 336, Lomé, Togo, monicadork@yahoo.fr.</nlm:affiliation><country wicri:rule="url">France</country><wicri:regionArea>Ministère de la Santé du Togo, BP 336, Lomé, Togo</wicri:regionArea><wicri:noRegion>Togo</wicri:noRegion><wicri:noRegion>Togo</wicri:noRegion></affiliation></author><author><name sortKey="Sodahlon, Y K" sort="Sodahlon, Y K" uniqKey="Sodahlon Y" first="Y K" last="Sodahlon">Y K Sodahlon</name></author><author><name sortKey="Bronzan, R N" sort="Bronzan, R N" uniqKey="Bronzan R" first="R N" last="Bronzan">R N Bronzan</name></author><author><name sortKey="Yakpa, K" sort="Yakpa, K" uniqKey="Yakpa K" first="K" last="Yakpa">K. Yakpa</name></author><author><name sortKey="Sossou, E" sort="Sossou, E" uniqKey="Sossou E" first="E" last="Sossou">E. Sossou</name></author><author><name sortKey="Ouro Medeli, A" sort="Ouro Medeli, A" uniqKey="Ouro Medeli A" first="A" last="Ouro-Medeli">A. Ouro-Medeli</name></author><author><name sortKey="Teko, M" sort="Teko, M" uniqKey="Teko M" first="M" last="Teko">M. Teko</name></author><author><name sortKey="Seim, A" sort="Seim, A" uniqKey="Seim A" first="A" last="Seim">A. Seim</name></author><author><name sortKey="Mathieu, E" sort="Mathieu, E" uniqKey="Mathieu E" first="E" last="Mathieu">E. Mathieu</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25476256</idno><idno type="pmid">25476256</idno><idno type="doi">10.1007/s13149-014-0408-z</idno><idno type="wicri:Area/PubMed/Corpus">001156</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001156</idno><idno type="wicri:Area/PubMed/Curation">001156</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001156</idno><idno type="wicri:Area/PubMed/Checkpoint">001156</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001156</idno><idno type="wicri:Area/Ncbi/Merge">006E07</idno><idno type="wicri:Area/Ncbi/Curation">006E07</idno><idno type="wicri:Area/Ncbi/Checkpoint">006E07</idno><idno type="wicri:doubleKey">0037-9085:2015:Dorkenoo A:lymphatic:filariasis:transmission</idno><idno type="wicri:Area/Main/Merge">001585</idno><idno type="wicri:Area/Main/Curation">001583</idno><idno type="wicri:Area/Main/Exploration">001583</idno><idno type="wicri:Area/France/Extraction">000059</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Lymphatic filariasis transmission assessment survey in schools three years after stopping mass drug treatment with albendazole and ivermectin in the 7 endemic districts in Togo].</title><author><name sortKey="Dorkenoo, A M" sort="Dorkenoo, A M" uniqKey="Dorkenoo A" first="A M" last="Dorkenoo">A M Dorkenoo</name><affiliation wicri:level="1"><nlm:affiliation>Ministère de la Santé du Togo, BP 336, Lomé, Togo, monicadork@yahoo.fr.</nlm:affiliation><country wicri:rule="url">France</country><wicri:regionArea>Ministère de la Santé du Togo, BP 336, Lomé, Togo</wicri:regionArea><wicri:noRegion>Togo</wicri:noRegion><wicri:noRegion>Togo</wicri:noRegion></affiliation></author><author><name sortKey="Sodahlon, Y K" sort="Sodahlon, Y K" uniqKey="Sodahlon Y" first="Y K" last="Sodahlon">Y K Sodahlon</name></author><author><name sortKey="Bronzan, R N" sort="Bronzan, R N" uniqKey="Bronzan R" first="R N" last="Bronzan">R N Bronzan</name></author><author><name sortKey="Yakpa, K" sort="Yakpa, K" uniqKey="Yakpa K" first="K" last="Yakpa">K. Yakpa</name></author><author><name sortKey="Sossou, E" sort="Sossou, E" uniqKey="Sossou E" first="E" last="Sossou">E. Sossou</name></author><author><name sortKey="Ouro Medeli, A" sort="Ouro Medeli, A" uniqKey="Ouro Medeli A" first="A" last="Ouro-Medeli">A. Ouro-Medeli</name></author><author><name sortKey="Teko, M" sort="Teko, M" uniqKey="Teko M" first="M" last="Teko">M. Teko</name></author><author><name sortKey="Seim, A" sort="Seim, A" uniqKey="Seim A" first="A" last="Seim">A. Seim</name></author><author><name sortKey="Mathieu, E" sort="Mathieu, E" uniqKey="Mathieu E" first="E" last="Mathieu">E. Mathieu</name></author></analytic><series><title level="j">Bulletin de la Societe de pathologie exotique (1990)</title><idno type="ISSN">0037-9085</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Albendazole (administration & dosage)</term><term>Albendazole (therapeutic use)</term><term>Animals</term><term>Anthelmintics (administration & dosage)</term><term>Anthelmintics (therapeutic use)</term><term>Antigens, Helminth (blood)</term><term>Child</term><term>Cross-Sectional Studies</term><term>Elephantiasis, Filarial (diagnosis)</term><term>Elephantiasis, Filarial (epidemiology)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Elephantiasis, Filarial (transmission)</term><term>Endemic Diseases (prevention & control)</term><term>Female</term><term>Government Programs</term><term>Health Promotion (organization & administration)</term><term>Health Surveys</term><term>Humans</term><term>Immunochromatography (instrumentation)</term><term>Ivermectin (administration & dosage)</term><term>Ivermectin (therapeutic use)</term><term>Male</term><term>Mass Screening</term><term>Microfilariae (isolation & purification)</term><term>Parasitemia (diagnosis)</term><term>Parasitemia (parasitology)</term><term>Practice Guidelines as Topic</term><term>Program Evaluation</term><term>Sampling Studies</term><term>School Health Services</term><term>Schools</term><term>Togo (epidemiology)</term><term>World Health Organization</term><term>Wuchereria bancrofti (immunology)</term><term>Wuchereria bancrofti (isolation & purification)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Albendazole (administration et posologie)</term><term>Albendazole (usage thérapeutique)</term><term>Animaux</term><term>Antigènes d'helminthe (sang)</term><term>Antihelminthiques (administration et posologie)</term><term>Antihelminthiques (usage thérapeutique)</term><term>Dépistage systématique</term><term>Enfant</term><term>Enquêtes de santé</term><term>Femelle</term><term>Filariose lymphatique ()</term><term>Filariose lymphatique (diagnostic)</term><term>Filariose lymphatique (transmission)</term><term>Filariose lymphatique (épidémiologie)</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Immunochromatographie (instrumentation)</term><term>Ivermectine (administration et posologie)</term><term>Ivermectine (usage thérapeutique)</term><term>Maladies endémiques ()</term><term>Microfilaria (isolement et purification)</term><term>Mâle</term><term>Organisation mondiale de la santé</term><term>Parasitémie (diagnostic)</term><term>Parasitémie (parasitologie)</term><term>Programmes gouvernementaux</term><term>Promotion de la santé (organisation et administration)</term><term>Services de santé scolaire</term><term>Togo (épidémiologie)</term><term>Wuchereria bancrofti (immunologie)</term><term>Wuchereria bancrofti (isolement et purification)</term><term>Établissements scolaires</term><term>Études par échantillonnage</term><term>Études transversales</term><term>Évaluation de programme</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antigens, Helminth</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Albendazole</term><term>Antihelminthiques</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Parasitemia</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Filariose lymphatique</term><term>Parasitémie</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Togo</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="instrumentation" xml:lang="en"><term>Immunochromatography</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Microfilariae</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Microfilaria</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="organisation et administration" xml:lang="fr"><term>Promotion de la santé</term></keywords><keywords scheme="MESH" qualifier="organization & administration" xml:lang="en"><term>Health Promotion</term></keywords><keywords scheme="MESH" qualifier="parasitologie" xml:lang="fr"><term>Parasitémie</term></keywords><keywords scheme="MESH" qualifier="parasitology" xml:lang="en"><term>Parasitemia</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Endemic Diseases</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Antigènes d'helminthe</term><term>Immunochromatographie</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term><term>Antihelminthiques</term><term>Filariose lymphatique</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Filariose lymphatique</term><term>Togo</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Child</term><term>Cross-Sectional Studies</term><term>Female</term><term>Government Programs</term><term>Health Surveys</term><term>Humans</term><term>Male</term><term>Mass Screening</term><term>Practice Guidelines as Topic</term><term>Program Evaluation</term><term>Sampling Studies</term><term>School Health Services</term><term>Schools</term><term>World Health Organization</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Dépistage systématique</term><term>Enfant</term><term>Enquêtes de santé</term><term>Femelle</term><term>Filariose lymphatique</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Maladies endémiques</term><term>Mâle</term><term>Organisation mondiale de la santé</term><term>Programmes gouvernementaux</term><term>Services de santé scolaire</term><term>Établissements scolaires</term><term>Études par échantillonnage</term><term>Études transversales</term><term>Évaluation de programme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this study is to verify the level of transmission of lymphatic filariasis three years after stopping mass drug treatment in the 7 endemic districts in Togo. The survey was conducted in 2012 in Togo's 7 endemic districts grouped into four evaluation units (EU) using the WHO-recommended transmission assessment survey (TAS) protocol. Children aged 6-7 years were screened for Wuchereria bancofti antigen using the immunochromatographic card (ICT) method. A cluster sampling method was used to select eligible children in schools as the net primary-school enrolment ratio is greater than or equal to 75% in each of the four EUs. The number of children and schools to be selected in each EU, the randomization list for the selection of these children and the critical cut-off number of positive cases not to exceed were automatically generated using the Survey Sample Builder (SSB) tool, (NTD Support Center, Atlanta, Ga, USA). For confirmation, positive cases were subsequently tested for microfilaremia using nocturnal thick blood smear and for filarial antigen using Og4C3 antigen ELISA (TropBio ELISA Kit®, Townsville, Queensland, Australia). An EU is considered to have passed the test successfully (it is assumed that transmission can no longer be sustained), when the number of positive cases is below the critical cut-off number set by the SSB, which is roughly equivalent to 2% prevalence. Of the 1 706 children surveyed in Kpendjal-Tone's EU, 1 549 in Binah-Doufelgou's EU, 1 550 in Kozah's EU and the 1 575 in Amou-Haho's EU, 8 (0.46%), 1 (0.08%), 0 (0.00%) and 4 (0.25%) ICT positive cases respectively were detected. The number of positive ICT tests was well below 18, the critical cut number for each of the 4 EUs. All 13 ICT positive cases tested negative for nocturnal microfilaremia and Og4C3 ELISA. We conclude that all four EU passed the TAS with success, and the transmission of Wuchereria bancrofti is no longer likely to be sustained in the 7 endemic districts in Togo 3 years after stopping the MDA. A new TAS will be carried out in 2015, after which, if the results are still good, the country will submit a dossier to WHO for verification of the elimination of lymphatic filariasis.</div></front></TEI><affiliations><list><country><li>France</li></country></list><tree><noCountry><name sortKey="Bronzan, R N" sort="Bronzan, R N" uniqKey="Bronzan R" first="R N" last="Bronzan">R N Bronzan</name><name sortKey="Mathieu, E" sort="Mathieu, E" uniqKey="Mathieu E" first="E" last="Mathieu">E. Mathieu</name><name sortKey="Ouro Medeli, A" sort="Ouro Medeli, A" uniqKey="Ouro Medeli A" first="A" last="Ouro-Medeli">A. Ouro-Medeli</name><name sortKey="Seim, A" sort="Seim, A" uniqKey="Seim A" first="A" last="Seim">A. Seim</name><name sortKey="Sodahlon, Y K" sort="Sodahlon, Y K" uniqKey="Sodahlon Y" first="Y K" last="Sodahlon">Y K Sodahlon</name><name sortKey="Sossou, E" sort="Sossou, E" uniqKey="Sossou E" first="E" last="Sossou">E. Sossou</name><name sortKey="Teko, M" sort="Teko, M" uniqKey="Teko M" first="M" last="Teko">M. Teko</name><name sortKey="Yakpa, K" sort="Yakpa, K" uniqKey="Yakpa K" first="K" last="Yakpa">K. Yakpa</name></noCountry><country name="France"><noRegion><name sortKey="Dorkenoo, A M" sort="Dorkenoo, A M" uniqKey="Dorkenoo A" first="A M" last="Dorkenoo">A M Dorkenoo</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000059 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000059 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= France
|étape= Analysis
|type= RBID
|clé= pubmed:25476256
|texte= [Lymphatic filariasis transmission assessment survey in schools three years after stopping mass drug treatment with albendazole and ivermectin in the 7 endemic districts in Togo].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/RBID.i -Sk "pubmed:25476256" \
| HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |